octreotide + pegvisomant

A **combination of octreotide** (a synthetic somatostatin analogue) and **pegvisomant** (a growth hormone receptor antagonist) primarily used in the management of **acromegaly** when monotherapy is insufficient to control insulin-like growth factor 1 (IGF-1) levels. Octreotide suppresses growth hormone (GH) secretion from the pituitary, while pegvisomant blocks GH action at the peripheral growth hormone receptor, thereby preventing IGF-1 production. This dual approach improves efficacy, is generally well-tolerated, and is especially considered when IGF-1 normalization cannot be achieved with either drug alone. The combination has shown to be effective and safe in long-term real-world and trial settings[1][2][3][4].

Brand names

Somatuline + SomavertSandostatin + Somavert

Other names

octreotide LAR + pegvisomantlong-acting octreotide + pegvisomantsomatostatin analogue + pegvisomant